SCHEMBL4184482

SCHEMBL4184482

CC(C)(C)NC(=S)N1CCC(OC(c2ccc(Cl)cc2)c2ccccc2Cl)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.48
CNR2 P34972 2/20 0.48
FAAH O00519 7/20 0.42
MEN1 O00255 2/20 0.40
MAPT P10636 2/20 0.40
KMT2A Q03164 2/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
THPO P40225 1/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
HTT P42858 1/20 0.40
GMNN O75496 1/20 0.39
LMNA P02545 1/20 0.39
PMP22 Q01453 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4189412 0.90 CNR1 (0.47) CNR1CNR2FAAH
SCHEMBL4180197 0.90 CNR1 (0.47) CNR1CNR2FAAH
SCHEMBL4180202 0.90 CNR1 (0.47) CNR1CNR2FAAH
SCHEMBL4193205 0.80 STS (0.49) CNR1CNR2FAAHMEN1MAPT
SCHEMBL5744774 0.80 DRD3 (0.46) FAAHMEN1MAPTKMT2ATP53
SCHEMBL4179785 0.80 FAAH (0.46) CNR1CNR2FAAHCYP3A4
SCHEMBL4179776 0.79 FAAH (0.50) CNR1CNR2FAAH
SCHEMBL4079568 0.79 CNR1 (0.60) CNR1CNR2FAAH
SCHEMBL4188659 0.78 FAAH (0.42) CNR1CNR2FAAH
SCHEMBL5466897 0.78 IDO1 (0.44) CNR1CNR2FAAHMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181939-A1 Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders VERNALIS RESEARCH LIMITED. (GB) 2009-07-16 US disclosed
US-20070173486-A1 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs VERNALIS RESEARCH LIMITED (GB) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181939-A1 Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders CNR1, CNR2, GPR119 CNR1 1/4885CNR2 2/4885FAAH 116/4885
US-20070173486-A1 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs CNR1, CNR2, GPR119 CNR1 1/4885CNR2 2/4885FAAH 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.